Navigation Links
Tengion Provides Update on Neo-Urinary Conduit Clinical Trial
Date:6/13/2011

EAST NORRITON, Pa., June 13, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today provided an update on the clinical trial of the Company's lead clinical product candidate, the Neo-Urinary Conduit™, for use in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy). Tengion is continuing to work with investigators to optimize the surgical approach as part of its ongoing clinical trial of the Neo-Urinary Conduit in patients with bladder cancer and is working closely with clinical investigators, the Data Safety Monitoring Board (DSMB) and the U.S. Food and Drug Administration (FDA) to advance the study.

"As planned, we have reviewed clinical data from our ongoing trial with the investigators, the DSMB, and the FDA," said Sunita Sheth, M.D., Chief Medical Officer and Vice President Clinical and Regulatory Affairs of Tengion. "Based on these discussions, a plan has been developed to collect additional clinical data while modifying the surgical approach for future implants.  We expect to submit these data and changes to the FDA in the third quarter, prior to enrolling additional patients in the trial."  

The study is designed to provide data on the safety profile and preliminary efficacy for the Neo-Urinary Conduit as an alternative to the current standard treatment requiring the use of a patient's own bowel tissue, which can cause significant complications, as well as to provide investigators with data to optimize the surgical technique and post-surgical patient care during the trial. To date, three patients have been enrolled and implanted in the clinical trial at both the University of Chicago Medical Center and at The Johns Hopkins Hospital in Baltimore, Maryland.

About Bladder Cancer

The National Cancer Institute estimates that more than 70,000 new cases of bladder cancer are diagnose
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tengion Announces FDA Orphan-Drug Designation for Neo-Urinary Conduit
2. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
3. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
4. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
5. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
6. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
7. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
8. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
9. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
10. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
11. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... is available in its catalogue: Global ... http://www.reportlinker.com/p01375204/Global-Coatings-for-Medical-Devices-Industry.html This report ... Devices in US$ Million by the following Product ... Nanotechnology Coatings. The report provides separate comprehensive analytics ...
(Date:8/20/2014)... and PHOENIX , ... established to bring cutting-edge next-generation sequencing and proteomic ... patients, today announced a collaboration with TESARO, Inc.  ... characterize patient tissue samples from clinical trials to ... resistant to TESARO,s TSR-011.  This may lead to more ...
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
Breaking Medicine Technology:Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... Inc. (Nasdaq: ENZN) announced today that four,posters containing ... Meeting of the American Association for Cancer Research,(AACR) ... 2007 in Los Angeles, CA., Details of the ... EZN-2208, a novel polyethyleneglycol-SN38,conjugate, has potent antitumor activity ...
... 13, 2007 - Point Therapeutics, Inc.,(NASDAQ: POTP) today ... 2007 Annual Meeting of the American,Association for Cancer ... 14-18, 2007. The AACR poster presentations report,on preclinical ... details for the AACR presentations are as,follows: , ...
Cached Medicine Technology:Enzon to Present Preclinical Data From PEG-SN38 and PEGylation,Technology Studies at AACR Meeting 2
(Date:8/21/2014)... 21, 2014 Denver marketing agency ... for the American Lung Association in Colorado’s 2014 ... welcome Webolutions as a sponsor,” said Curt Huber, Chief ... Executive Director, American Lung Association in Colorado, “and we’re ... in this role they’ve defined.” , Webolutions has also ...
(Date:8/21/2014)... August 21, 2014 If chocolate is good ... will soon be very happy and healthy. Tracie is the ... Break ” contest. She and three of her coworkers will ... luxuriate at the world-famous Chocolate Spa® at The Hotel Hershey® ... third year working in the ambulatory surgery center at Connecticut ...
(Date:8/21/2014)... Rockville Centre, NY (PRWEB) August 21, 2014 ... injury law firm with over 25 years of experience ... dangerous prescription drugs and defective medical devices, announces the ... offer information to those women who believe they have ... The site offers valuable information about the severe adverse ...
(Date:8/21/2014)... Michael E. Steuer , local doctor ... to the Bluff City with recent philanthropy at local synagogue. ... the United States,” says friend and Rabbi David Julian of ... such as providing in-house for the needy and teaching Hebrew ... in the local synagogue. And to remain close with the ...
(Date:8/21/2014)... August 21, 2014 InSilico ... interventions and addressing the challenges of a ... OncoFinder, for signalome-wide pathway analysis. This ... cross-platform analysis of gene expression data obtained ... published in the journal Frontiers in Molecular ...
Breaking Medicine News(10 mins):Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3Health News:Connecticut Nurse Wins a Sweet Prize from California Casualty 2Health News:Rottenstein Law Group LLP Announces Launch of WeHelpWomen.com 2Health News:OncoFinder, a new algorithm for minimizing errors in high-throughput transcriptome analysis 2
... INDIANAPOLIS, Sept. 14 In conjunction with today,s announcement ... to patients, Eli Lilly and Company (NYSE: ... Center of Excellence and its five business units: oncology, ... These leaders will provide improved line of sight to ...
... in dementia care is not so much related to equipment ... communication problems and misunderstandings. This is shown in a new ... Sweden. Dementia not only affects the memory and other ... to walk. ,The symptoms of dementia are very individual ...
... , AHIP to leverage MedAssurant,s datasets and ... affordability of healthcare. , , WASHINGTON, ... Inc., announced today that MedAssurant, through its healthcare data analytics ... quality and effectiveness of treatments. , , ...
... boosting the odds, experts say, , MONDAY, Sept. 14 (HealthDay ... the odds that a child will develop asthma or allergies, ... spent more than 1,000 hours swimming in chlorinated pools, either ... of having asthma than did teens who primarily swam in ...
... , , NCCN is ... forum to discuss the regulatory and operational aspects of research ... improvements can be made. Scheduled for October 26 - 27 ... and panel discussions on topics that challenge the conduct of ...
... Schizophrenia is a major public health problem. Affecting almost ... economic and social toll in addition to the distress, ... disease. Elements of the disease are present from birth, ... becomes fully expressed in early adulthood with long-lasting implications ...
Cached Medicine News:Health News:Lilly Names New Business Leaders 2Health News:Lilly Names New Business Leaders 3Health News:Lilly Names New Business Leaders 4Health News:Lilly Names New Business Leaders 5Health News:Lilly Names New Business Leaders 6Health News:Lilly Names New Business Leaders 7Health News:Lilly Names New Business Leaders 8Health News:Communication problems in dementia care cause physical strain 2Health News:MedAssurant to Support AHIP's Research Capabilities 2Health News:Chlorine in Pools Raises Kids' Asthma, Allergy Risk 2Health News:Chlorine in Pools Raises Kids' Asthma, Allergy Risk 3Health News:NCCN Holds Oncology Research Best Practices Conference 2Health News:NCCN Holds Oncology Research Best Practices Conference 3Health News:The future of schizophrenia 2Health News:The future of schizophrenia 3Health News:The future of schizophrenia 4Health News:The future of schizophrenia 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: